Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company - - Added late-stage pediatric onset rare disease asset, protein kinase C β isoform
Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end
RUBY trial of EDIT-301 for sickle cell disease active and recruiting
Preclinical ocular data presented at ARVO supports in vivo gene editing
$723 million
as of March 31, 2021
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021.
“Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for our two clinical-stage medicines,” said James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine. “We are pleased to announce Dr. Mark Shearman will be joining Editas as Chief Scientific Officer in June 2021. Mark has an outstanding track record of drug discovery and development, and we are confident that
Published: May 05, 2021
Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end
RUBY trial of EDIT-301 for sickle cell disease active and recruiting
Preclinical ocular data presented at ARVO supports in vivo gene editing
$723 million
as of March 31, 2021
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021.
“Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for our two clinical-stage medicines,” said James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine. “We are pleased to announce Dr. Mark Shearman will be joining Editas as Chief Scientific Officer in June 2021. Mark has an outstanding track record of drug discovery and development